APA

Smith P. F., Krishnarajah J., Nunn P. A., Hill R. J., Karr D., Tam D., Masjedizadeh M., Funk J. O. & Gourlay S. G. (20180612). A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. : British journal of clinical pharmacology.

Chicago

Smith Patrick F, Krishnarajah Janakan, Nunn Philip A, Hill Ron J, Karr Dane, Tam D, Masjedizadeh Mohammad, Funk Jens O and Gourlay Steve G. 20180612. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. : British journal of clinical pharmacology.

Harvard

Smith P. F., Krishnarajah J., Nunn P. A., Hill R. J., Karr D., Tam D., Masjedizadeh M., Funk J. O. and Gourlay S. G. (20180612). A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. : British journal of clinical pharmacology.

MLA

Smith Patrick F, Krishnarajah Janakan, Nunn Philip A, Hill Ron J, Karr Dane, Tam D, Masjedizadeh Mohammad, Funk Jens O and Gourlay Steve G. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. : British journal of clinical pharmacology. 20180612.